P50.13 A Nomogram for Assessing Survival in Extensive-stage SCLC Patients with SVCS Referred to Thoracic Radiotherapy: Upfront Vs. Consolidative ?
T. Mei,W. Xiu,X. Yang,Y. Yu,J. Zhu,Y. Xu,M. Huang,J. Xue,L. Zhou,X. Zhou,Y. Liu,Y. Lu,Y. Gong
DOI: https://doi.org/10.1016/j.jtho.2021.01.1652
IF: 20.121
2021-01-01
Journal of Thoracic Oncology
Abstract:We aimed to develop and validate a nomogram to predict the impact of the time of radiotherapy on the survival of ES-SCLC patients with SVCS. Between 2009 and 2017, ES-SCLC patients with SVCS were recruited in present study. We integrated the important factors affecting survival and built a nomogram. The model was subjected to bootstrap internal validation, and patients were randomly divided into training and validation cohorts (7:3). The cox proportional hazard model is used to select factors with significant differences to build the nomogram. Concordance index (C-index) and risk group stratification are used to measure the prediction accuracy and discriminative ability of the model. Sex (female vs. male , hazard ratio (HR), 0.57; 95%CI, 0.374-0.869, p=0.009), age(<60 years vs. ≥60 years, HR 0.73, ; 95%CI, 0.504-1.04, p=0.084) ECOG performance status(PS=2 vs. PS=0-1, HR 2.31, 95%CI, 1.51-3.51, p<0.001), distant metastases(liver: yes vs. no, HR 1.61, 95%CI, 1.09-2.37, p=0.016;bone: yes vs. no ,HR 2.07, 95%CI, 1.38-3.11, p<0.001;brain: yes vs. no, HR 1.49, 95%CI, 1.01-2.21, p=0.045; retroperitoneal lymph node: yes vs. no, HR 2.53, 95%CI, 1.58-4.04, p<0.001; supraclavicular lymph node: yes vs. no, HR 1.68, 95%CI, 1.00-2.83, p=0.052;) and treatment (chemotherapy alone vs. chemotherapy-based consolidative thoracic radiotherapy (cc-TRT) vs. chemotherapy-based upfront thoracic radiotherapy (cu-TRT), HR 1.28, 95%CI, 1.00-1.64, p=0.056) were entered into the nomogram. The bootstrapped-concordance index of the nomogram was 0.764. And the area under the curve of 3-, 6-, 9-months, 1-, 2-year was 1, 0.9, 0.8, 0.8, 0.87, respectively. The calibration curves also showed good consistency in the probability of 3-, 6-, 9-months, 1-,2-years survival time between the actual observation and the nomogram prediction. A risk classification system was established and patients were divided into high-risk and low-risk groups. Univariate analysis suggested a poorer prognosis in the high-risk groups than in the low-risk groups in all three groups (all cohorts, training cohort, validation cohort, all p < 0.01). We established and validated a novel nomogram that can provide an individual prediction of OS for ES-SCLC patients with SVCS. From this nomogram, the strategy of cu-TRT has a significant positive impact on the prognosis of ES-SCLC patients with SVCS. Further studies are warranted to verify these findings